PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Amgen Inc. with access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ human antibody generation platforms, jointly known as OmniAb™. Amgen becomes OMT’s 12th non-academic partner globally with such multi-platform access.
Dr. Roland Buelow, OMT founder and CEO, said, “Amgen was an early protein therapeutics leader and became one of a few companies with transgenic mouse platforms for human antibody discovery in 2005 when they acquired Abgenix and its XenoMouse®. With the license from OMT, Amgen further builds on this capability as it gains access to complementary platforms for development of fully human, mono- and bispecific antibodies without any target restrictions.”
Help employers find you! Check out all the jobs and post your resume.
Dr. Roland Buelow, OMT founder and CEO, said, “Amgen was an early protein therapeutics leader and became one of a few companies with transgenic mouse platforms for human antibody discovery in 2005 when they acquired Abgenix and its XenoMouse®. With the license from OMT, Amgen further builds on this capability as it gains access to complementary platforms for development of fully human, mono- and bispecific antibodies without any target restrictions.”
Help employers find you! Check out all the jobs and post your resume.
